Fairscale Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.6K Hold
74
– – 0.01% 312
2026
Q2
$9.35K Hold
74
– – 0.01% 320
2026
Q1
$10.3K Hold
74
– – 0.01% 312
2025
Q4
$9.08K Hold
74
– – 0.01% 304
2025
Q3
$8.21K Hold
74
– – 0.01% 337
2025
Q2
$8.31K Buy
74
+58
+363% +$6.17K 0.01% 336
2025
Q1
$1.79K Hold
16
– – ﹤0.01% 306
2024
Q4
$1.48K Hold
16
– – ﹤0.01% 316
2024
Q3
$1.34K Hold
16
– – ﹤0.01% 316
2024
Q2
$1.15K Buy
+16
New +$1.07K ﹤0.01% 328

Other funds holding GILD

Fairscale Capital's GILD Position: Q3 2026 in Review

Fairscale Capital held its Gilead Sciences (GILD) position steady in Q3 2026 at 74 shares worth $12.6K. The position accounts for 0.01% of the portfolio, ranked #312.

Fairscale Capital first reported a position in GILD in Q2 2024 and has held it in 10 quarters since. 2,348 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Fairscale Capital held 74 shares of Gilead Sciences worth $12.6K as of Q3 2026.
  • Fairscale Capital left its Gilead Sciences share count unchanged in Q3 2026.
  • Gilead Sciences made up 0.01% of Fairscale Capital's portfolio in Q3 2026, its #312 holding.
  • Fairscale Capital first reported a position in Gilead Sciences in Q2 2024 and has held it in 10 quarters since.
  • 2,348 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Fairscale Capital's 13F filing for Q3 2026, filed 4 Nov 2026.